Navigation Links
Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Date:7/28/2008

Japan Market To Benefit from Novel Ingredients and Regulatory Expertise

PROVO, Utah, July 28 /PRNewswire-FirstCall/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced that the company has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.

Nu Skin Enterprises is the first direct selling company to have such an agreement with Toyo Bio-Pharma. The companies' collaborative development efforts will focus on sharing scientific and regulatory insights, as well as developing proprietary nutraceutical and cosmeceutical products for Nu Skin sales through its worldwide distribution network.

"We expect this relationship with Nu Skin Enterprises to nicely complement our current expertise in natural health supplements," said Yoshi Shiraishi, president and chief operating officer of Toyo Bio-Pharma. "We highly respect the industry-leading research and development capabilities of Nu Skin Enterprises. We believe there is a synergy between the two research teams that both companies can benefit from."

"Toyo Bio-Pharma is a subsidiary of Toyo Shinyaku, which is one of the most reputable supplement and skin care manufacturers in Japan, and we look forward to developing a robust relationship with joint development opportunities," said Joseph Chang, Ph. D., chief scientific officer and executive vice president of product development at Nu Skin Enterprises. "We are eager to leverage their knowledge of navigating regulatory requirements for skin care and supplements in Japan."

About Toyo Bio-Pharma

Toyo Bio-Pharma(TM) (http://www.toyobiopharma.com) is a subsidiary of Toyo Shinyaku Co., Ltd., a research-driven manufacturer committed to providing consumers and clients with high-value ingredients derived from nature. With the most advanced instrumentation, continuous research and commitment to quality and integrity, Toyo Shinyaku is pioneering the use of fermentation and culturing to produce beneficial, effective products for use in the nutraceutical, functional food and cosmeceuticals industries. Toyo Shinyaku is Japan's largest developer of FOSHU (Food for Specialized Health Use) products and ODM (Original Design Manufacturer) of supplement and skin care products. Toyo Shinyaku follows rigorous standards of ISO 9001:2000 and ISO 22000:2005, and was one of the first Japanese companies to become Food and Drug Administration (FDA) Good Manufacturing Practices (GMP)-compliant for food products and dietary supplements.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc. is a global direct selling company operating in 47 markets throughout Asia, the Americas and Europe. The company markets premium-quality personal care products under the Nu Skin(R) brand, science-based nutritional supplements under the Pharmanex(R) brand, and technology-based products and services under the Big Planet(R) brand. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskinenterprises.com.


'/>"/>
SOURCE Nu Skin Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nu Skin Enterprises to Announce Second Quarter 2008 Results
2. Medline Receives Force Majeure Notice From Hong Ray Enterprises
3. Nu Skin Enterprises to Present at Oppenheimer Consumer Growth Conference
4. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant
5. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
6. Nu Skin Enterprises Announces Slate of Candidates for its Board of Directors
7. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
8. Nu Skin Enterprises Declares Quarterly Dividend of $0.11
9. Nu Skin Enterprises Reports First-Quarter 2008 Results
10. FFF Enterprises Selects A10 Networks AX Series Advanced Traffic Manager
11. CJPS Enterprises Announces a Series of Seminars on Automotive Diversification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play in ... minimum two times a day that dentists recommend. The ramifications of improper oral upkeep go ... and adults missing 164 million hours of work each year due to dental issues. That ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... City (PRWEB) , ... March 23, 2017 , ... After ... fall, FaceCradle , the most-funded travel pillow in crowdfunding history, has ... delivery of its wildly popular travel innovation to Americans. , “We’re excited to be ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the ... poor sleep is likely not the only cause of the sunken-eye look, which can ... you look older or in poor health are likely due to genetics, dehydration, allergies, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... March 23, 2017 Ascendis Pharma A/S (Nasdaq: ... technology to address significant unmet medical needs in rare ... conference call and webcast on Monday, April 3 during ... in Orlando, Florida , to discuss ... (TransCon Growth Hormone, TransCon PTH and TransCon CNP). ...
(Date:3/23/2017)... , March 23, 2017  Cornerstone ... announced a major milestone today.  Following successful ... the U.S. Food and Drug Administration (FDA), ... clinical and regulatory path forward to conduct ... in patients with acute myeloid leukemia (AML) ...
Breaking Medicine Technology: